Diagnoses of *Shigella flexneri* in the United Kingdom (UK) are usually travel-related. However, since 2009, there has been an overall increase in UK-acquired cases. The Health Protection Agency has been investigating a national outbreak of *S. flexneri* detected in 2011 and which is still ongoing. Cases occurred mostly in men who have sex with men and were of serotype 3a. The investigation aimed at obtaining epidemiological data to inform targeted outbreak management and control.

Cases of *Shigella flexneri* in the United Kingdom (UK) usually originate from travel or contact with travellers from higher incidence regions such as Indian subcontinent, North and East Africa and South America [1]. Following analyses of laboratory data, an increase in UK-acquired *S. flexneri* cases was detected in London in November 2010. A subsequent rise in UK-acquired cases was also noted in Manchester in May 2011. The initial cases reported were predominantly of serotype 3a and mostly among men who have sex with men (MSM) aged between 30 and 50 years, some of whom were HIV positive. Pulsed field gel electrophoresis (PFGE) performed on initial stool specimen showed that some of the isolates were indistinguishable, however preliminary investigation failed to identify a common venue or point source [2,3].

In response, a national outbreak control team was formally established in September 2011 to investigate and manage the outbreak of *S. flexneri*. Enhanced surveillance was initiated in order to:

- describe the epidemiology of *S. flexneri* infection in individuals who had no travel history or who had travelled to countries with low risk for infection;
- estimate the proportion of UK-acquired cases or cases associated with travel in low-risk countries that are explained by transmission in MSM;
- identify risk factors for transmission of *S. flexneri* between MSM.

Sexual transmission of *Shigella* was first described in the United States during the 1970s [4]. Since then, several outbreaks of sexually transmitted *Shigella*, predominantly in MSM, have been reported [5-8]. In 2006, an outbreak of *Shigella* among MSM in London coincided with a similar outbreak in Berlin suggesting that travel plays a role in introducing *Shigella* species to populations at risk [9,10].

### Outbreak investigation

National enhanced surveillance of *S. flexneri* was conducted from September to December 2011 inclusive, in order to describe and monitor the epidemiology of the outbreak. The population under surveillance consisted of UK-acquired *S. flexneri* infection cases and reported cases associated with travel in low-risk countries.

Low-risk travel-associated individuals were defined as individuals who returned to the UK in the four days before onset of illness after travel to countries with low risk for *Shigella* infection (Europe, North America and Australia). High-risk travel-associated diagnoses were defined as individuals who returned to the UK in the four days before onset of illness after travel to countries with high risk for *Shigella* infection (South America, Asia and Africa) [1].

A confirmed case was defined as a laboratory-confirmed case of *S. flexneri* with a specimen date from 2009–2011.
between 1 September and 31 December 2011 with no recent travel or who reported recent travel to low-risk countries.

A probable case was defined as a laboratory-confirmed case of *S. flexneri* with an unknown travel history.

Cases of *S. flexneri* among people who had travelled to high-risk countries or secondary cases of *S. flexneri* who were contacts of high risk travel-associated cases were excluded.

All laboratories were asked to notify *Shigella* isolations and to send stool specimens to the national reference laboratory (Gastrointestinal Infections Reference Unit, Health Protection Agency - Colindale, London) for serotyping, PFGE analysis and sensitivity testing. Weekly updates on laboratory-confirmed *S. flexneri* diagnoses were forwarded to the respective regions for further follow-up.

Local health protection units confirmed the travel history for every reported *S. flexneri* diagnosis and conducted an interview using a surveillance questionnaire for UK-acquired or low-risk travel-associated diagnoses of *S. flexneri*. The questionnaire contained additional questions on exposures such as travel, food history, contact with symptomatic individuals and sexual contact to assist with case management. In-depth interviews with confirmed MSM cases were also conducted to identify potential risk factors for infection. *S. flexneri* reports from the national laboratory databases, regions and local units were collected and analysed and feedback was disseminated to the regional units and identified leads through epidemiological update reports.

Increased awareness and guidance for health professionals and people at risk of infection was issued through HPA briefings, information leaflets and press releases [11].

*S. flexneri* diagnoses reported by the national laboratories between 2001 and 2011 were also analysed to provide context to the current outbreak and to produce historical time trends.

### Results

During the enhanced surveillance period between September and December 2011, 145 *S. flexneri* diagnoses were reported of which 37 (25.5%) were non-travel related. Thirty-one cases were confirmed as being UK-acquired whereas six reported diagnoses were likely to be secondary cases linked to a symptomatic contact with recent travel to a high-risk country.

Eighty-six cases (59.3%) were associated with travel to high-risk countries and the travel history was unknown for 22 individuals (15.2%). No low-risk travel-associated cases of *S. flexneri* were reported during the enhanced surveillance period.

The UK-acquired cases were predominantly male (n=26) whereas travel-associated *S. flexneri* diagnoses were equally distributed between both sexes: 48% male (n=40) and 52% female (n=43) as shown in Figure 1. The sex and age of three travel-associated cases was not known.

### Figure 1

**Cases of Shigella flexneri** reported during the enhanced surveillance period by age group and sex, England and Wales, September – December 2011

<table>
<thead>
<tr>
<th>A</th>
<th>United Kingdom-acquired cases (n=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female (n=5)</td>
</tr>
<tr>
<td>1</td>
<td>1-10</td>
</tr>
<tr>
<td>2</td>
<td>11-20</td>
</tr>
<tr>
<td>3</td>
<td>21-30</td>
</tr>
<tr>
<td>4</td>
<td>31-40</td>
</tr>
<tr>
<td>5</td>
<td>41-50</td>
</tr>
<tr>
<td>6</td>
<td>51-60</td>
</tr>
<tr>
<td>7</td>
<td>61-70</td>
</tr>
<tr>
<td>8</td>
<td>Number of cases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B</th>
<th>Travel-associated cases (n=83)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female (n=43)</td>
</tr>
<tr>
<td>1</td>
<td>1-10</td>
</tr>
<tr>
<td>2</td>
<td>11-20</td>
</tr>
<tr>
<td>3</td>
<td>21-30</td>
</tr>
<tr>
<td>4</td>
<td>31-40</td>
</tr>
<tr>
<td>5</td>
<td>41-50</td>
</tr>
<tr>
<td>6</td>
<td>51-60</td>
</tr>
<tr>
<td>7</td>
<td>61-70</td>
</tr>
<tr>
<td>8</td>
<td>Number of cases</td>
</tr>
</tbody>
</table>

* The gender and age of three travel-associated cases was not known.

Source: National reference laboratory database (GDW- Gastro Data Warehouse), Health Protection Agency, Colindale, United Kingdom.
National laboratory reporting database (LabBase 2), Health Protection Agency, Colindale, United Kingdom.
Eleven male cases with UK-acquired *S. flexneri* reported MSM activity in the week before developing gastroenteritis. Three individuals refused to disclose their sexual orientation.

Ten of the 31 reported UK-acquired *S. flexneri* cases were serotype 3a, seven were serotype 1b, five were serotype 2a, three were serotype 6 and one case was reported for serotypes 1a, 1c, 2b and 3b. The serotype was unknown for two reported *S. flexneri* diagnoses. More than half (n=5) of the infections in MSM were caused by serotype 3a, four by serotype 1b, one by serotype 2a and one by serotype 6.

In depth interviews with seven MSM cases showed that they all had one long term partner and attended regular medical examinations. However, all cases reported having a casual sexual partner in the week preceding illness. These interviews revealed lack of awareness about *Shigella* and of the risks associated with unprotected oral and oral-anal sex.

Trends in *S. flexneri* diagnoses reported between 2001 and 2011 showed a gradual increase in the number of cases with no or unknown history of travel since 2001, with a similar trend in both sexes until 2008 (Figure 2). However, from 2009 onwards, numbers of diagnoses rose far more rapidly in men (Figure 2).

Data analysis revealed similar trends in cases between sexes and within the same age group, however, since 2009 the increase in the number of *S. flexneri* cases reported was attributable to an overrepresentation of men aged between 31 and 50 years (Figure 3).

The increase in serotype 3a since 2009 was mostly attributable to diagnoses among men aged 30-50 years which constituted 65% (211/324) of all *S. flexneri* 3a reports with no or unknown travel history between 2009 and 2011. When focusing on the male adult cases with serotype 3a, the number of monthly *S. flexneri* diagnoses in 2007/2008 fluctuates between 1 and 7 cases. The number of monthly reports increases to between 5 and 15 from 2009 onwards. The following graph shows the number of monthly diagnoses from

---

**Figure 2**

*Shigella flexneri* cases with no or unknown travel history stratified by year and sex, England and Wales, 2001–2011 (n=3,352)

Source: National laboratory reporting database (LabBase 2), Health Protection Agency, Colindale, United Kingdom.

**Figure 3**

*Shigella flexneri* cases by sex and age group, England and Wales, (A) 2001–2008 (n=2,026) and (B) 2009–2012 (n=1,239)

Source: National laboratory reporting database (LabBase 2), Health Protection Agency, Colindale, United Kingdom.
2007-2012 and a three-month moving average (Figure 5).

Control measures
The outbreak control team introduced control measures which focused on actions aimed at prompt and effective management of cases to prevent onward transmission. They included increasing awareness among clinicians and MSM and prompt diagnosis and treatment, increased testing of MSM with diarrhoea and treatment of laboratory-confirmed cases with ciprofloxacin [12] subject to antimicrobial sensitivity.

These actions also included recommendations regarding behaviours that may contribute to prevent further transmission:

- wash hands after using toilet, before preparing or eating food and after sexual activity;
- avoid anal sex, oral-anal sex, scat and rimming whilst symptomatic and until test for infection shows clearance;
- use of condoms, gloves, dental dams during sex;
- avoid sharing douching materials and sex toys;
- avoid swimming pools and spa centres whilst ill and for two weeks after recovery.

Work is ongoing to identify risk factors for infection and evaluate other possible control measures such as screening of asymptomatic contacts.

Discussion and conclusion
As the outbreak is still ongoing and no similar S. flexneri outbreaks have recently been reported by other countries, increased vigilance and monitoring by other European countries is recommended in order to promptly and effectively detect any change in the reported trends of S. flexneri.

Although some people may have been reluctant to disclose details about their sexual orientation, the enhanced surveillance revealed a strong association between UK-acquired S. flexneri and transmission in MSM. The outbreak will continue to be monitored through routine arrangements and information on cases occurring in MSM will continue to be collected in order to effectively describe the epidemiology of the disease in MSM and identify any potential risk factors to inform public health action.
Although the *S. flexneri* outbreak first emerged in 2009 and has been sustained since then, it has only been detected relatively recently. An evaluation of *Shigella* infection surveillance will therefore be carried out in order to identify factors leading to the delay in outbreak identification and to explore new approaches to routine surveillance of sexually-transmitted *Shigella* infection.

References


